The Pan American Health Organization (PAHO) has published its first evidence-based guide for tungiasis treatment. The parasite burrows into the skin and causes intense inflammation, pain, burning and itching, especially on the feet. Children and older adults are the most affected and the disease can cause chronic complications and social stigma.
The guide recommends low-viscosity dimethicone as the preferred treatment and ivermectin if dimethicone is not available. It warns against manual removal without antiseptic measures or trained staff. Common sharp tools for removal include needles, scissors and hairpins. The guide also discourages potassium permanganate and hydrogen peroxide because they can burn or irritate the skin.
PAHO says infections are concentrated in ten countries. More than 70 per cent of reported cases between 2010 and 2022 were in Brazil, mainly in Amazonian villages. PAHO estimates 450 million people live in at-risk areas, but many cases go unreported because of stigma and limited access to healthcare.
Difficult words
- flea — A small insect that bites animals.
- treatment — Ways to help make a person better.
- pain — A feeling of hurt or discomfort.
- poverty — The state of being very poor.poverty-stricken
- guidelines — Recommended rules or instructions.
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- Why do you think tungiasis mainly affects people in poverty?
- How can healthcare policies help prevent diseases like tungiasis?
- What other treatments do you think could work for tungiasis?
Related articles
Engineered bacteria produce tagatose sweetener
Tufts researchers engineered Escherichia coli to make tagatose, a rare sugar that can substitute for table sugar. They used a slime mold enzyme and another enzyme to convert glucose, producing higher yields; tagatose is low‑calorie and FDA‑recognized as safe.
AI is changing basic health care in sub‑Saharan Africa
Artificial intelligence is already helping basic medical care in parts of sub‑Saharan Africa. Pilot projects in Kenya, Ghana and Rwanda show faster diagnosis, fewer wrong prescriptions and quicker delivery of blood and imaging results.
Emory study: 2023–24 COVID vaccine gives lasting antibodies
Emory University measured antibody responses in 24 people after the 2023–24 monovalent vaccine targeting Omicron XBB.1.5. The study found long-lasting antibodies, cross-reactive protection with the ancestral WA1 strain, and a 2.8-fold boost from immune imprinting.
Rwanda strengthens response to Rift Valley Fever outbreak
Rwanda reported a second Rift Valley Fever outbreak near the Tanzania border and has increased surveillance and livestock vaccination. Officials say lack of rapid diagnostic tests slows detection, while a human vaccine candidate enters Phase II trials.